Research programme: isocitrate dehydrogenase inhibitors - Daiichi Sankyo/National Cancer CenterAlternative Names: DS-1001; DS-1001b; IDH1 inhibitors - Daiichi Sankya/National Cancer Cantre
Latest Information Update: 07 Jan 2017
At a glance
- Originator Daiichi Sankyo Company; National Cancer Center (Tokyo)
- Class 1 ring heterocyclic compounds; Antibodies; Antineoplastics; Isoxazoles
- Mechanism of Action Isocitrate dehydrogenase 1 inhibitors; Isocitrate dehydrogenase 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
- Phase Unknown Glioma